SPOTLIGHT: Kosan touts Hsp90 results

Sweden's Kosan Biosciences says that preliminary results of a Phase I trial of its experimental heat shock protein 90 inhibitor showed signs of antiocancer activity and tolerability. Several biotechs are racing to develop Hsp90 inhibitors, including Infinity Pharmaceuticals, which researchers believe will ultimately lead to a treatment that can kill of cancer cells. Release

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.